Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Provides Corporate Update
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland , Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic
View HTML
Toggle Summary Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a
View HTML
Toggle Summary Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Nov.
View HTML
Toggle Summary Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its
View HTML
Toggle Summary Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a
View HTML
Toggle Summary Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- Topline Data Expected First Quarter 2023 - DUBLIN, Ireland and FORT WASHINGTON, Pa. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious
View HTML
Toggle Summary Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the
View HTML
Toggle Summary Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa. , July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its
View HTML
Toggle Summary Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
DUBLIN, Ireland and FORT WASHINGTON, Pa. , July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com